1. Home
  2. HITI vs SGMT Comparison

HITI vs SGMT Comparison

Compare HITI & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo High Tide Inc.

HITI

High Tide Inc.

HOLD

Current Price

$2.46

Market Cap

189.8M

Sector

N/A

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$10.22

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
HITI
SGMT
Founded
2009
2006
Country
Canada
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
189.8M
169.4M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
HITI
SGMT
Price
$2.46
$10.22
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
8
Target Price
$6.13
$26.13
AVG Volume (30 Days)
394.0K
1.3M
Earning Date
06-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,000,000.00
Revenue This Year
$23.73
N/A
Revenue Next Year
$12.80
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.02
$4.50
52 Week High
$4.06
$11.15

Technical Indicators

Market Signals
Indicator
HITI
SGMT
Relative Strength Index (RSI) 67.72 68.92
Support Level $2.35 $6.16
Resistance Level $2.54 N/A
Average True Range (ATR) 0.08 0.69
MACD 0.02 0.12
Stochastic Oscillator 87.27 77.50

Price Performance

Historical Comparison
HITI
SGMT

About HITI High Tide Inc.

High Tide Inc is a downstream-focused retailer of cannabis products, distributor, and seller of smoking accessories and cannabis lifestyle products. It is a vertically integrated company in the Canadian cannabis market with various brands in its portfolio such as Canna Cabana, Fastendr, Queen of Bud, Grasscity, Daily High Club, and others. The company's reportable operating segments are: Bricks and mortar, which generates maximum revenue, and E-commerce. Geographically, it derives maximum revenue from its business in Canada, followed by the United States of America, and other international markets.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: